PharmGen Science Inc (004720) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of PharmGen Science Inc stock KRW 3,707, price KRW 2,955, upside +25.4%, quality 39 out of 100. Rating: undervalued. Calculated from audited financials with 13 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range 2,710 KRW – 14,800 KRW · fair‑value band 2,451 KRW – 4,770 KRW · the 2,955 KRW price screens below the 3,707 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow PharmGen Science in your weekly email
Every Wednesday you see whether PharmGen Science is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
PharmGen Science, Inc. engages in the research and development, production, and sale of pharmaceutical products in South Korea.
Show moreShow less
It provides prescription drugs, OTC drugs, diagnostic test kits, health and general foods, and cosmetics, as well as shampoo, conditioner, and hair oil products under the neomcell brand name.
The company was formerly known as Wooridul Pharmaceutical Limited and changed its name to PharmGen Science, Inc. PharmGen Science, Inc. was founded in 1957 and is headquartered in Hwaseong-si, South Korea.
Stock analysis
PharmGen Science Inc (004720) currently trades at 2,955 KRW, while our model-based Fair Value estimate is 3,707 KRW, implying the stock looks roughly 20% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 5,054 KRW per share, and 10 of the 13 models we run sit above the 2,955 KRW price.
Bear case: the Asset-Based group reads lowest at 2,077 KRW, and 3 of the 13 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 2,451 KRW (bear) to 4,770 KRW (bull), the price of 2,955 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
PharmGen Science Inc reported revenue of 173B KRW in FY2025 versus 110B KRW in FY2021, a compound +12.0%/yr. Reported net income was −117B KRW in FY2025.
Key figures
Market cap 64.8B KRW (≈ $47.9M) Micro · P/E ratio 569.5 · P/S ratio 0.38 · EPS (TTM) 5.21 KRW · Net margin 0.1% · Return on equity 0.1% · Return on assets (EBIT) 1.8% (5-year average) · Operating margin 4.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 25 out of 100 (medium confidence).
What moves the price
The share trades about 33% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −11% fair-value upside, at 25%, 004720 screens cheaper than that median.
Fair Value models
Bear2,451 KRWFair Value 3,707 KRWBull4,770 KRW
Price 2,955 KRW · Upside +25.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (4.47 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF2,898 KRW4,502 KRW7,331 KRW79
Growth DCF2,884 KRW4,361 KRW6,905 KRW77
5Y EBITDA Exit4,664 KRW8,074 KRW12,414 KRW74
All 13 models by family
DCF Models
FCF DCF2,898 KRW4,502 KRW7,331 KRW79
5Y Revenue Exit3,202 KRW5,054 KRW7,596 KRW72
5Y EBITDA Exit4,664 KRW8,074 KRW12,414 KRW74
10Y Revenue Exit3,002 KRW4,739 KRW7,449 KRW66
10Y EBITDA Exit4,062 KRW6,967 KRW11,513 KRW66
Earnings-Based
EPV2,235 KRW2,451 KRW2,640 KRW74
Multiples
EV/EBIT3,361 KRW4,487 KRW5,612 KRW66
EV/EBITDA4,883 KRW6,516 KRW8,148 KRW67
EV/Revenue2,395 KRW3,428 KRW4,460 KRW53
Asset-Based
NCAV (Graham)1,371 KRW2,077 KRW2,596 KRW54
Growth DCF
Growth DCF2,884 KRW4,361 KRW6,905 KRW77
Rev-Margin DCF3,202 KRW4,993 KRW7,308 KRW72
Economic Profit
ROIC Compounder2,235 KRW2,451 KRW2,640 KRW72
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.65/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+1.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.4%
Start year 2020 (pandemic). Over 10 years: +11.1% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+5.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +3.6% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 74 stocks
Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score39 · Bottom 25%
Fair Value upside+25.7% · Top 25%
Profitability
Return on equity (12 months)0.1% · Bottom 25%
Return on assets−59.7% · Bottom 25%
Net margin (12 months)0.1% · Bottom 25%
Operating margin (12 months)4.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)0.9% · Bottom 25%
Balance sheet
Debt / equity0.00× · Lowest 25%
Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper
P/E (12 months)569.5× · Priciest 25%
P/B0.44× · Cheapest 25%
P/S (12 months)0.38× · Cheapest 25%
Price / free cash flow (fiscal year)24.4× · Pricier than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is PharmGen Science Inc (004720) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 3,707 KRW versus a price of 2,955 KRW, about +25% upside (undervalued).
What is the fair value of 004720?
Our model-based fair value for PharmGen Science Inc is 3,707 KRW (as of Nov 9, 2026), built from audited fundamentals. The current price: 2,955 KRW.
What is the quality score of 004720?
PharmGen Science Inc has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for PharmGen Science Inc (004720)?
Our model-based price target is the fair value of 3,707 KRW (as of Nov 9, 2026) from 13 valuation models. Cautious scenario 2,451 KRW, optimistic scenario 4,770 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the PharmGen Science Inc stock forecast for 2026?
Our models put fair value at 3,707 KRW, about +25% upside versus a price of 2,955 KRW (undervalued). Cautious scenario 2,451 KRW, optimistic scenario 4,770 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of PharmGen Science Inc (004720)?
PharmGen Science Inc reported trailing-twelve-month revenue of about 172B KRW (latest available figure, as of Nov 9, 2026).
What growth is priced into PharmGen Science Inc (004720)?
For today's price to be fair in a discounted-cash-flow model, PharmGen Science Inc would have to grow free cash flow by +5.8 % per year for five years (discount rate 8.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +12.4 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of 004720 use?
Our models discount PharmGen Science Inc at 8.9 %: a base by market capitalisation (nano), damped by beta 0.38, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For PharmGen Science Inc that is +5.8 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.9 %) and the same formula as our fair value.
How much growth has PharmGen Science Inc (004720) delivered so far?
Over the past 5 years revenue at PharmGen Science Inc grew +12.4 % a year. The price currently implies free-cash-flow growth of +5.8 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of PharmGen Science Inc (004720) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into PharmGen Science Inc (+5.8 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of PharmGen Science Inc (004720)?
The free-cash-flow yield on the price is 4.09 %: that much free cash flow PharmGen Science Inc produces per unit of market value. When it exceeds the discount rate of our models (8.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of PharmGen Science Inc (004720)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For PharmGen Science Inc it is 3,707 KRW per share (as of Nov 9, 2026), against a price of 2,955 KRW. It is the blended result of 13 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit).
Is PharmGen Science Inc stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 004720 trades below its calculated fair value: price 2,955 KRW, fair value 3,707 KRW, a gap of about +25% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 004720?
No. The price is what the market pays today (2,955 KRW); the fair value is what the company's own numbers justify (3,707 KRW). For PharmGen Science Inc the two are 751.83 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is PharmGen Science Inc worth?
The market values PharmGen Science Inc at about 64.8B KRW (market capitalisation, as of Nov 9, 2026). Per share that is 2,955 KRW; our models calculate a fair value of 3,707 KRW per share.
What do the bullish and bearish scenarios say about 004720?
Our models span a range for PharmGen Science Inc: cautious scenario 2,451 KRW, base 3,707 KRW, optimistic 4,770 KRW per share (as of Nov 9, 2026, price 2,955 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of PharmGen Science Inc (004720)?
Balance-sheet figures for PharmGen Science Inc (as of Nov 9, 2026): return on equity 0.1%, debt of 0.00 per unit of equity. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is 004720 from its 52-week high?
PharmGen Science Inc trades at 2,955 KRW, about 33% below its 52-week high of 4,400 KRW and 9% above the low of 2,710 KRW (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 3,707 KRW is for.
Which stocks are comparable to PharmGen Science Inc?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is PharmGen Science Inc stock attractive at the current price?
The data as of Nov 9, 2026: price 2,955 KRW, calculated fair value 3,707 KRW (+25%), Quality Score 39/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 004720 calculated?
We run PharmGen Science Inc through 13 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit. Every model gets the same audited fundamentals; the fair value of 3,707 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. PharmGen Science Inc currently trades 20% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of PharmGen Science Inc (004720)?
The closing price on Nov 9, 2026 was 2,955 KRW. Our model-based fair value is 3,707 KRW, about +25% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with PharmGen Science Inc right now?
A fairly wide model range (2,451 KRW to 4,770 KRW) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of PharmGen Science Inc
How large is the market capitalisation of PharmGen Science Inc (004720)?
The market capitalisation of PharmGen Science Inc is 64.8B KRW (≈ $47.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of PharmGen Science Inc (004720)?
The price-to-earnings ratio of PharmGen Science Inc is 569.5 (· median at FY-end 19.1 (9 FY)). Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of PharmGen Science Inc (004720)?
The price-to-sales ratio of PharmGen Science Inc is 0.38 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of PharmGen Science Inc (004720)?
Earnings per share at PharmGen Science Inc are 5.21 KRW (price ÷ EPS = P/E 569.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of PharmGen Science Inc (004720)?
The net margin of PharmGen Science Inc is 0.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of PharmGen Science Inc (004720)?
The return on equity (ROE) of PharmGen Science Inc is 0.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of PharmGen Science Inc (004720)?
On an EBIT basis the return on assets of PharmGen Science Inc is 1.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of PharmGen Science Inc (004720)?
The operating margin of PharmGen Science Inc is 4.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at PharmGen Science Inc (004720)?
Revenue at PharmGen Science Inc is growing +0.9% versus a year earlier (3y avg +4.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at PharmGen Science Inc (004720)?
Earnings per share at PharmGen Science Inc are growing +55.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does PharmGen Science Inc (004720) carry?
The net debt of PharmGen Science Inc is 319M KRW (fiscal year 2024, ≈ 0.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch PharmGen Science Inc in the live analysis
One click puts PharmGen Science Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 9, 2026